Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial - the MIRO trial

Nicolas Briez, Guillaume Piessen, Franck Bonnetain, Cécile Brigand, Nicolas Carrere, Denis Collet, Christophe Doddoli, Renaud Flamein, Jean-Yves Mabrut, Bernard Meunier, Simon Msika, Thierry Perniceni, Frédérique Peschaud, Michel Prudhomme, Jean-Pierre Triboulet, Christophe Mariette, Nicolas Briez, Guillaume Piessen, Franck Bonnetain, Cécile Brigand, Nicolas Carrere, Denis Collet, Christophe Doddoli, Renaud Flamein, Jean-Yves Mabrut, Bernard Meunier, Simon Msika, Thierry Perniceni, Frédérique Peschaud, Michel Prudhomme, Jean-Pierre Triboulet, Christophe Mariette

Abstract

Background: Open transthoracic oesophagectomy is the standard treatment for infracarinal resectable oesophageal carcinomas, although it is associated with high mortality and morbidity rates of 2 to 10% and 30 to 50%, respectively, for both the abdominal and thoracic approaches. The worldwide popularity of laparoscopic techniques is based on promising results, including lower postoperative morbidity rates, which are related to the reduced postoperative trauma. We hypothesise that the laparoscopic abdominal approach (laparoscopic gastric mobilisation) in oesophageal cancer surgery will decrease the major postoperative complication rate due to the reduced surgical trauma.

Methods/design: The MIRO trial is an open, controlled, prospective, randomised multicentre phase III trial. Patients in study arm A will receive laparoscopic-assisted oesophagectomy, i.e., a transthoracic oesophagectomy with two-field lymphadenectomy and laparoscopic gastric mobilisation. Patients in study arm B will receive the same procedure, but with the conventional open abdominal approach. The primary objective of the study is to evaluate the major postoperative 30-day morbidity. Secondary objectives are to assess the overall 30-day morbidity, 30-day mortality, 30-day pulmonary morbidity, disease-free survival, overall survival as well as quality of life and to perform medico-economic analysis. A total of 200 patients will be enrolled, and two safety analyses will be performed using 25 and 50 patients included in arm A.

Discussion: Postoperative morbidity remains high after oesophageal cancer surgery, especially due to major pulmonary complications, which are responsible for 50% of the postoperative deaths. This study represents the first randomised controlled phase III trial to evaluate the benefits of the minimally invasive approach with respect to the postoperative course and oncological outcomes in oesophageal cancer surgery.

Trial registration: NCT00937456 (ClinicalTrials.gov).

Figures

Figure 1
Figure 1
Study flow chart.

References

    1. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545–53. doi: 10.1016/S1470-2045(07)70172-9.
    1. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–9. doi: 10.1056/NEJMoa022343.
    1. Gemmill EH, McCulloch P. Systematic review of minimally invasive resection for gastro-esophageal cancer. Br J Surg. 2007;94:1461–7. doi: 10.1002/bjs.6015.
    1. Decker G, Coosemans W, De Leyn P, Decaluwé H, Nafteux P, Van Raemdonck D, Lerut T. Minimally invasive esophagectomy for cancer. Eur J Cardiothorac Surg. 2009;35:13–20. doi: 10.1016/j.ejcts.2008.09.024.
    1. Berger AC, Bloomenthal A, Weksler B, Evans N, Chojnacki KA, Yeo CJ, Rosato EL. Oncologic efficacy is not compromised, and may be improved with minimally invasive esophagectomy. J Am Coll Surg. 2011;212:560–6. doi: 10.1016/j.jamcollsurg.2010.12.042.
    1. Bresadola V, Terrosu G, Cojutti A, Benzoni E, Baracchini E, Bresadola F. Laparoscopic versus open gastroplasty in esophagectomy for esophageal cancer: a comparative study. Surg Laparosc Endosc Percutan Tech. 2006;16:63–7. doi: 10.1097/00129689-200604000-00001.
    1. Bernabe KQ, Bolton JS, Richardson WS. Laparoscopic hand-assisted versus open transhiatal esophagectomy: a case-control study. Surg Endosc. 2005;19:334–7. doi: 10.1007/s00464-004-8807-z.
    1. Nguyen NT, Follette DM, Wolfe BM, Schneider PD, Roberts P, Goodnight JE Jr. Comparison of minimally invasive esophagectomy with transthoracic and transhiatal esophagectomy. Arch Surg. 2000;135:920–5. doi: 10.1001/archsurg.135.8.920.
    1. Smithers BM, Gotley DC, Martin I, Thomas JM. Comparison of the outcomes between open and minimally invasive esophagectomy. Ann Surg. 2007;245:232–40. doi: 10.1097/01.sla.0000225093.58071.c6.
    1. Biere SS, Maas KW, Bonavina L, Garcia JR, van Berge Henegouwen MI, Rosman C, Sosef MN, de Lange ES, Bonjer HJ, Cuesta MA, van der Peet DL. Traditional invasive vs. minimally invasive esophagectomy: a multi-center, randomized trial (TIME-trial) BMC Surg. 2011;11:2. doi: 10.1186/1471-2482-11-2.
    1. D'journo XB, Michelet P, Avaro JP, Trousse D, Giudicelli R, Fuentes P, Doddoli C, Thomas P. Respiratory complications after oesophagectomy for cancer. Rev Mal Respir. 2008;25:683–94.
    1. Jagot P, Sauvanet A, Berthoux L, Belghiti J. Laparoscopic mobilization of the stomach for oesophageal replacement. Br J Surg. 1996;83:540–2. doi: 10.1002/bjs.1800830435.
    1. Bonavina L, Bona D, Binyom PR, Peracchia A. A laparoscopy-assisted surgical approach to esophageal carcinoma. J Surg Res. 2004;117:52–7. doi: 10.1016/j.jss.2003.11.007.
    1. Godiris-Petit G, Munoz-Bongrand N, Honigman I, Cattan P, Sarfati E. Minimally invasive esophagectomy for cancer: prospective evaluation of laparoscopic gastric mobilization. World J Surg. 2006;30:1434–40. doi: 10.1007/s00268-005-0627-3.
    1. Cense HA, Busch OR, Bemelman WA, Obertop H, van Lanschot JJ. Results of the ecombination of open transthoracic esophagectomy with laparoscopic gastric tube formation for esophageal cancer. Dig Surg. 2006;23:164–8. doi: 10.1159/000094350.
    1. Holscher AH, Schneider PM, Gutschow C, Schroder W. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg. 2007;245:241–6. doi: 10.1097/01.sla.0000245847.40779.10.
    1. Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111:518–26.
    1. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumours. 7. New York: Wiley-Liss; 2010.
    1. Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, Legoux JL, Rougier P, Bedenne L, Seitz JF. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer. 2010;46:2753–62. doi: 10.1016/j.ejca.2010.07.023.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する